I-Mab
We are preparing, please wait
Undervalued or Overvalued?
Unfortunately, this content is only accessible to registered users
Login to ContinueKey stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Market Cap
$144.80 M
Change
-$0.06
EPS
-$2.48
P/E Growth
-0.76
New Bund Center, Shanghai, 200124
Sector:
Industry:
Fiscal Year-end
December
Revenue
$27.64 M
Net Income
$-1,465,694,000
2023 Sales Growth
0.00%
I-Mab's CEO, Mr. Raj Kannan
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Price
P/E CURRENT
$0.94
Changes Percentage
P/E CURRENT
-6.01%
Change
P/E CURRENT
-$0.06
Year High
P/E CURRENT
$2.54
An income statement known as a profit and loss statement, is a financial report that summarizes a company's revenues, expenses, gains, and losses over a specific period. It provides insight into a company's operational efficiency and profitability, helping investors and stakeholders assess financial performance and make informed decisions.
The Financials Balance Sheet report provides a clear and concise visual summary of a company’s financial standing through interactive charts. This section highlights key components such as assets, liabilities, and equity, offering investors an at-a-glance understanding of the company's financial health. By showcasing these critical metrics in an easy-to-digest format, the report enables stakeholders to evaluate the company’s stability, operational efficiency, and capital structure, fostering more informed investment decisions.
The Financials Cash Flow report uses charts to provide a clear breakdown of a company’s cash flow across operating, investing, and financing activities. This visualization helps investors quickly assess how the company generates, spends, and manages cash, offering valuable insights into its liquidity and financial efficiency.
Market Benchmark Score
Market Score: Aggregate the average P/E ratio of all companies in the market.
Industry Score: Aggregate the average P/E ratio of all companies in the same industry.
ASSETS
$2.61 B
LIABILITIES
$894.81 M
DEBT Equity Ratio
0.00
Operating Cash Flow
$-184,091,358
The latest Technical Analysis Summary on Stocks.News offers insights into market trends using key Technical Indicators like RSI and MACD, alongside Moving Averages such as the 50-day and 200-day. The analysis identifies buy and sell signals through bullish or bearish crossovers, helping investors make informed trading decisions.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Today's price of I-Mab is $0.94 — it has decreased by -6.01%
Yes, you can track I-Mab's financials in yearly and quarterly reports directly on Stocks.News.
Watch the I-Mab chart and read a more detailed I-Mab stock forecast to see what analysts suggest you do with its shares.
The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by I-Mab stock ticker.
Like other stocks, IMAB shares are sold on stock exchanges such as NASDAQ The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.
I-Mab measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in I-Mab’s financial statements.
